{
    "organizations": [],
    "uuid": "63bec0884aba70705b0420fb020c437b06cc2a36",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-integral-diagnostics-sees-fy-norma/brief-integral-diagnostics-sees-fy-normalised-npat-growth-of-around-20-pct-idUSFWN1P60ZH",
    "ord_in_thread": 0,
    "title": "BRIEF-Integral Diagnostics Sees FY Normalised NPAT Growth Of Around 20 pct",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 12 (Reuters) - Integral Diagnostics Ltd:\n* ‍CAPITAL EXPENDITURE FOR FULL YEAR IS FORECAST AT $17M​ * EXPECTS ACHIEVEMENT OF FULL YEAR NORMALISED NPAT GROWTH OF AROUND 20% (BEFORE TAKEOVER RESPONSE COSTS AND TRANSACTION COSTS) Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-01-12T08:06:00.000+02:00",
    "crawled": "2018-01-12T18:35:48.027+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "integral",
        "diagnostics",
        "ltd",
        "expenditure",
        "full",
        "year",
        "forecast",
        "expects",
        "achievement",
        "full",
        "year",
        "normalised",
        "npat",
        "growth",
        "around",
        "takeover",
        "response",
        "cost",
        "transaction",
        "cost",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}